## Amendments to the Claims

1. (Currently Amended) A method for treating cancer in a cancer patient with p53 mutation comprising:

administering 5-fluorouracil to the patient; and

administering to the cancer patient 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin at least 1 day before or after administering 5-fuorouracil to the patient and when 5-fluorouracil is not present in a pharmaceutically active form in the patient.

## 2-12. (Canceled)

- 13. (Previously Presented) A method according to claim 1 wherein 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 2 days after 5-fluorouracil is administered.
- 14. (Previously Presented) A method according to claim 1 wherein 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 3 days after 5-fluorouracil is administered.
- 15. (Previously Presented) A method according to claim 1 wherein 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 4 days after 5-fluorouracil is administered.
- 16. (Previously Presented) A method according to claim 1 wherein 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 5 days after 5-fluorouracil is administered.
- 17. (Canceled)
- 18. (Currently Amended) A method according to claim 1 wherein 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 2 and 90 days before or after 5-fluorouracil is administered and is also administered within 2 days of when 5-fluorouracil is administered.

Appl. No. 10/081,974

Amdt. dated April 19, 2005

Reply to Office Action of Dec. 2, 2004

19. (Currently Amended) A method according to claim 1 wherein 9-nitro-20(S)-

camptothecin or 9-amino-20(S)-camptothecin is administered between 3 and 90 days before or

after 5-fluorouracil is administered and is also administered within 3-days of when 5-fluorouracil

is-administered.

20. (Currently Amended) A method according to claim 1 wherein 9-nitro-20(S)-

camptothecin or 9-amino-20(S)-camptothecin is administered between 4 and 90 days before or

after 5-fluorouracil is administered and is also administered within 4-days of when 5-fluorouracil

is administered.

21. (Previously Presented) A method according to claim 1 wherein the patient has pancreatic

cancer.

22-24. (Canceled)

25. (Previously Presented) A method according to claim 1 wherein the patient has cancer

selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic

myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric

sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostrate, and

stomach cancer.

26-53. (Canceled)

Attorney Docket No. 12636-263 C:\NrPortbl\PALIB1\DH1\2602942 1.DOC 3